Evidence map›Paper›PMID 40762872›Full record

ReviewAnnals of intensive care2025

IFNγ in human sepsis: a scoping review.

Daniel Thomas-Rüddel, Evangelos Giamarellos-Bourboulis, Caroline Neumann, Josef Briegel, Antoine Roquilly, Djillali Annane, Reinhard Wetzker, Michael Bauer, iRECORDS study group

Abstract readReview
In one paragraph

Review in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Octreotide Counteracts IFN-γ-Induced Endothelial Inflammation.Journal of biochemical and molecular toxicology · 2026
    Article
  3. Observational
  4. Article
  5. Article
  6. The Dual Role of Natural Killer Cells in the Septic Liver.Journal of inflammation research · 2026
    Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel Thomas-RüddelDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Evangelos Giamarellos-Bourboulis4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Caroline NeumannDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Josef BriegelDepartment of Anesthesiology, University Hospital, LMU Munich, Munich, Germany.
Antoine RoquillyCenter for Research in Transplantation and Translational Immunology, UMR 1064; and Anesthesie Reanimation, Nantes Université, CHU Nantes, INSERM, CIC 1413, Nantes, France.
Djillali AnnaneDepartment of Intensive Care, Raymond Poincaré Hospital, APHP, University Versailles Saint Quentin-University Paris Saclay, INSERM, Garches, France.
Reinhard WetzkerDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
Michael BauerDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany. Michael.Bauer@med.uni-jena.de.ORCID http://orcid.org/0000-0002-1521-3514
iRECORDS study group

Funding

Bundesministerium für Bildung und Forschung 01KU2209Deutsche Forschungsgemeinschaft EXC2051
6 · The paper itself

Abstract

backgroundThe cytokine IFNγ is released primarily by lymphocytes to initiate and orchestrate immune responses in a broad range of target cells. Whereas immune cells release inflammatory mediators and initiate antimicrobial responses when stimulated by IFNγ, parenchymal cells frequently display increased immunogenicity and incidental cell death. In addition to these well-characterized effects of IFNγ, recent studies disclose a key role of the cytokine in sepsis and organ dysfunction. MAIN: This review summarizes current knowledge on the IFNγ response to infection and attempts to relate the IFNγ response to endophenotypes of sepsis in the human host. Both, excessive pro-inflammatory responses with high IFNγ and downstream mediators, such as chemokines (CXCL9), as well as immunosuppression with low IFNγ levels are associated with unfavorable outcomes in sepsis. Pilot studies suggested beneficial effects of recombinant IFNγ in counteracting immunosuppression associated with low IFNγ levels. On the other hand, IFNγ may induce macrophages to release chemokines CXCL9, 10, and 11 to attract B and T lymphocytes to the sites of infection. Downstream induction of CXCL9 (but not of CXCL10 and 11) occurring in a subset of patients with high IFNγ levels has been shown to correlate with the hyper-inflammatory phenotype of sepsis. Both, high- and low-expressing IFNγ phenotypes of sepsis, might be related to nucleotide polymorphisms of the human IFNγ gene.

conclusionAssociation of IFNγ activity states with sepsis outcome renders this key regulatory protein of immunity a top candidate for theranostic interventions in a "personalized medicine approach" to infection and sepsis, especially when combined with additional biomarkers, such as CXCL9, reflecting or even mediating maladaptive downstream actions.

Indexed as

HyperinflammationIFNγImmunostimulatory therapyImmunosuppressionImmunosuppressive therapySepsis

Identifiers

PMID40762872
PMCPMC12325153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.